diphenhydramine Side Effects
Also known as: Benadryl
Analysis of 60,533 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
60,533
Death-Related
11,360
18.8% of reports
Hospitalizations
19,529
32.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 11,360 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 2,805 |
| TOXICITY TO VARIOUS AGENTS | 2,776 |
| DEATH | 2,291 |
| DRUG ABUSE | 1,610 |
| CARDIO-RESPIRATORY ARREST | 781 |
| CARDIAC ARREST | 677 |
| OFF LABEL USE | 586 |
| OVERDOSE | 550 |
| RESPIRATORY ARREST | 472 |
| PNEUMONIA | 452 |
| FATIGUE | 444 |
| DYSPNOEA | 358 |
| PAIN | 356 |
| PYREXIA | 355 |
| HEADACHE | 334 |
| HYPERTENSION | 321 |
| NAUSEA | 300 |
| INTENTIONAL PRODUCT MISUSE | 297 |
| INFUSION RELATED REACTION | 289 |
| VOMITING | 282 |
Reactions in Hospitalization Reports
Top reactions in 19,529 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 2,542 |
| PNEUMONIA | 2,033 |
| NAUSEA | 1,772 |
| FATIGUE | 1,710 |
| PYREXIA | 1,663 |
| HEADACHE | 1,627 |
| PAIN | 1,539 |
| DYSPNOEA | 1,534 |
| DRUG INEFFECTIVE | 1,302 |
| MALAISE | 1,283 |
| VOMITING | 1,224 |
| ARTHRALGIA | 1,223 |
| FEBRILE NEUTROPENIA | 1,211 |
| DIARRHOEA | 1,199 |
| WEIGHT DECREASED | 1,191 |
| COVID-19 | 1,159 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 1,153 |
| FALL | 1,148 |
| SINUSITIS | 1,098 |
| CONDITION AGGRAVATED | 1,061 |
Nearby — Related Medications
What the FAERS Data Reveals About diphenhydramine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 60,533 voluntary reports linked to diphenhydramine and its brand equivalents (Benadryl), spanning 2003 through 2025. Of those, 11,360 (18.8%) listed death as an outcome and 19,529 (32.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 64% were female and 36% male; age distribution skews toward 45-64, with 13,785 reports in that bracket. The single most reported reaction is off label use with 7,772 submissions, followed by headache and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.